Choi WM, Kim JY, Choi J, et al. - Researchers examined the link between the baseline and kinetics of the neutrophil‐lymphocyte ratio (NLR) and clinical results among nivolumab‐treated hepatocellular carcinoma (HCC) patients. This study comprised 194 cases; most patients were men (82.0%) and had a Child‐Pugh class A disease (70.6%). A poorer overall survival was experienced by patients with a baseline NLR ≥3 vs those with baseline NLR <3. During therapy, a rapid rise in NLR was seen in patients developing hyperprogression (HPD) and only a ΔNLR at 4 weeks was identified as predictive of HPD. HPD risk rose by 20% for every 20% increment in the ΔNLR at 4 weeks. An elevated risk of death was observed in relation to an NLR increase at 4 weeks, particularly in cases with a baseline NLR ≥ 3. Findings demonstrate the effectiveness of baseline as well as on‐treatment kinetics for the NLR as prognostic indicators in nivolumab‐treated HCC cases.